Anlon Healthcare AGM 2026: ₹1,533 Cr Share Swap

AGM date, time, and what shareholders will vote on

Anlon Healthcare Limited has called its 13th Annual General Meeting (AGM) for September 5, 2026, where shareholders will be asked to approve a large share-swap led acquisition of two pharma entities. The meeting is scheduled to start at 11:00 am and will be held via video conference. The company has positioned the proposal as a step to make Apiqo Organics Private Limited (AOPL) and Bizotic Lifescience Private Limited (BLPL) wholly owned subsidiaries. The acquisition is structured as a preferential allotment for consideration other than cash. Alongside the acquisition, the AGM agenda also includes capital and governance-related resolutions.

Proposed acquisitions: Apiqo Organics and Bizotic Lifescience

The main resolution seeks approval for Anlon Healthcare to acquire up to 44.94% of Apiqo Organics and up to 47.41% of Bizotic Lifescience. The company has stated that these purchases will result in both entities becoming wholly owned subsidiaries after completion. The acquisition structure relies on issuing fresh equity shares of Anlon Healthcare to the selling shareholders of AOPL and BLPL. There is no cash consideration under the proposed structure, based on the disclosures. The company has described the transaction as a share swap using predetermined exchange ratios. Any fractional entitlements arising from the exchange are to be rounded off to the nearest whole equity share.

Preferential allotment: number of shares and issue price

To execute the swap, Anlon Healthcare proposes to issue up to 8,58,83,617 fully paid-up equity shares. These shares have a face value of ₹2 each and will be issued at ₹17.85 per share, which includes a security premium of ₹15.85. The company has also referred to the deal as a ₹1,533 crore consideration transaction in its AGM-related communication. The issue price was benchmarked against a regulatory floor price. The floor price for the issue was determined at ₹17.78 per equity share, based on the volume-weighted average price on the National Stock Exchange during the 90 trading days preceding August 6, 2026.

Swap ratios and entity-wise allotment plan

The share exchange ratio disclosed for AOPL shareholders is 1:14.45, while for BLPL shareholders it is 1:8.96. Based on the entity-wise allotment schedule shared by the company, the majority of swap shares are planned for the Apiqo Organics leg. The disclosures also include separate consideration values for each entity. These figures provide clarity on how the preferential issue is distributed between the two targets.

Key acquisition terms (as disclosed)

Correction to stake percentages and what changed

Anlon Healthcare has disclosed that it corrected the acquisition stakes to 44.94% for Apiqo Organics and 47.41% for Bizotic Lifescience. The earlier figures cited were 32.52% for AOPL and 43.33% for BLPL, which were later replaced by the revised numbers. The company said the revision does not change the aggregate consideration or the exchange ratios. On August 13, 2026, the company clarified it will acquire up to 44.94% in AOPL and up to 47.41% in BLPL, replacing the previously reported stake percentages. The core deal structure remains a share swap, with no cash outflow expected from Anlon Healthcare.

Other AGM items: directors and related approvals

Beyond the acquisition, shareholders will also vote on director-related resolutions. The company has proposed the reappointment of Punitkumar Rameshbhai Rasadia, who retires by rotation. It has also proposed the appointment of Kishan Vinodkumar Raja as an Independent Director. These items are part of the standard governance agenda that accompanies major corporate actions. The company’s AGM notice also references compliance-related attachments, including a monitoring agency report for the quarter ended June 30, 2026, and other filings under SEBI (LODR) regulations.

Authorised capital increase: ₹110 crore to ₹130 crore

Anlon Healthcare is seeking approval to enhance its authorised share capital from ₹110 crore to ₹130 crore. The proposal includes creating 10 crore additional equity shares of ₹2 each. This resolution is relevant in the context of a large preferential allotment and future capital flexibility. An increase in authorised capital expands the ceiling for issuing new shares under the company’s capital structure. The AGM will decide whether the company gets shareholder consent for this headroom.

Trading window closure and board meeting context

The company announced the closure of its trading window for promoters, directors, key managerial personnel, and designated persons, effective August 6, 2026. It said the window will remain closed until 48 hours after the conclusion of the upcoming Board of Directors meeting scheduled for August 11, 2026. The board meeting is linked to approvals around preferential issue and AGM matters, as disclosed in its meeting intimation. Separately, the company’s corporate actions calendar referenced multiple dates connected to preferential issue and AGM-related items.

Market snapshot and key dates to track

Anlon Healthcare was reported as trading at ₹14.22 on August 13, 2026 at 05:04:47, down 0.07% versus the previous close of ₹14.23. While the AGM vote is the key near-term event, investors are also tracking board meeting outcomes and subsequent regulatory filings. The timeline below captures the major dates that were referenced alongside the transaction disclosures.

Why the resolutions matter for shareholders

The preferential allotment is central because it changes the equity base through issuance of up to 8,58,83,617 new shares. The acquisition resolution and the authorised capital increase are linked in that both address the company’s ability to execute and accommodate the proposed swap. The director appointments are part of the broader governance decisions shareholders must approve at the AGM. The floor price disclosure is also relevant because it shows how the pricing benchmark was determined for the preferential issue. Finally, the corrected stake percentages matter because they clarify the extent of ownership Anlon aims to consolidate in AOPL and BLPL.

Conclusion

Anlon Healthcare’s September 5, 2026 AGM is set to be a decisive shareholder vote on a share-swap acquisition designed to make Apiqo Organics and Bizotic Lifescience wholly owned subsidiaries. The agenda also includes a proposal to raise authorised share capital to ₹130 crore and approve key board appointments. The next formal milestones highlighted in the disclosures are the board meeting scheduled for August 11, 2026 and the AGM vote itself. Investors will likely track the company’s post-meeting filings for the final set of approvals and allotment steps.